Implant Strategy-Specific Changes in Symptoms in Response to Left Ventricular Assist Devices.

J Cardiovasc Nurs

Christopher S. Lee, PhD, RN, FAHA, FAAN, FHFSA Carol A. Lindeman Distinguished Professor, School of Nursing and Knight Cardiovascular Institute, Oregon Health & Science University, Portland. Jill M. Gelow, MD, MPH Assistant Professor, Knight Cardiovascular Institute, Oregon Health & Science Universi

Published: July 2019


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Although we know that the quality of life generally improves after left ventricular assist device (LVAD) implantation, we know little about how symptoms change in response to LVAD.

Methods: The purpose of this study was to compare the changes in symptoms between bridge and destination therapy patients as part of a prospective cohort study. Physical (dyspnea and wake disturbances) and affective symptoms (depression and anxiety) were measured before LVAD and at 1, 3, and 6 months after LVAD. Multiphase growth modeling was used to capture the 2 major phases of change: initial improvements between preimplant and 1 month after LVAD and subsequent improvements between 1 and 6 months after LVAD.

Results: The sample included 64 bridge and 22 destination therapy patients as the preimplant strategy. Destination patients had worse preimplant dyspnea and wake disturbances, and they experienced greater initial improvements in these symptoms compared with bridge patients (all P < .05); subsequent change in both symptoms were similar between groups (both P > .05). Destination patients had worse preimplant depression (P = .042) but experienced similar initial and subsequent improvements in depression in response to LVAD compared with bridge patients (both P > .05). Destination patients had similar preimplant anxiety (P = .279) but experienced less initial and greater subsequent improvements in anxiety after LVAD compared with bridge patients (both P < .05).

Conclusion: There are many differences in the magnitude and timing of change in symptom responses to LVAD between bridge and destination therapy patients. Detailed information on changes in specific symptoms may better inform shared decision-making regarding LVAD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173804PMC
http://dx.doi.org/10.1097/JCN.0000000000000430DOI Listing

Publication Analysis

Top Keywords

bridge destination
12
destination therapy
12
therapy patients
12
subsequent improvements
12
destination patients
12
compared bridge
12
bridge patients
12
patients
9
changes symptoms
8
left ventricular
8

Similar Publications

Left Ventricular Assist Devices: Advances, Complications, and Pitfalls.

Radiol Cardiothorac Imaging

August 2025

Department of Imaging Sciences-Cardiothoracic Imaging, University of Rochester Medical Center, 691 Elmwood Ave, Rochester, NY 14642.

Left ventricular assist devices (LVADs) are used for short-term support, as a bridge to transplant, or as destination therapy in patients with end-stage systolic heart failure. Imaging plays a crucial role in assessing the anatomic suitability for implantation and in detecting complications following both implantation and explantation. LVAD-associated complications can affect the pump, inflow cannula, outflow graft, or driveline.

View Article and Find Full Text PDF

Extracorporeal membrane oxygenation in cardiogenic shock: A bridge in need of a destination.

J Heart Lung Transplant

August 2025

Division of Critical Care Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article and Find Full Text PDF

ECPELLA as a Bridge to Unexpected Myocardial Recovery in a Patient in Refractory Cardiogenic Shock.

JACC Case Rep

August 2025

Department of Cardiovascular Disease, Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA. Electronic address:

Cardiogenic shock (CS) is a complex, multifactorial syndrome with substantial morbidity and mortality. Despite neutral results from randomized controlled trials, venoarterial extracorporeal membrane oxygenation (VA-ECMO) may be reasonable for select patients with refractory CS. A 37-year-old woman with morbid obesity and dilated nonischemic cardiomyopathy presented with Society of Cardiovascular Angiography and Intervention stage D biventricular CS, requiring vasopressor support and emergent escalation to ECPELLA, the combination of VA-ECMO and Impella (Abiomed), as a bridge to decision.

View Article and Find Full Text PDF

Mechanical circulatory support (MCS) devices have evolved significantly over the past decades and play a vital role in managing end-stage heart failure, especially as a bridge to heart transplantation. From the pioneering heart-lung machines to third-generation ventricular assist devices (VADs), MCS technology has advanced to provide more durable, efficient, and safer options for both shortand long-term support. This review outlines the historical development of mechanical assist devices, the types of available supports - ranging from intra-aortic balloon pumps and extracorporeal membrane oxygenation to implantable devices like HeartMate 3 - and their clinical indications and complications.

View Article and Find Full Text PDF

Background: Continuous-flow left ventricular assist devices (LVADs) are increasingly used as destination therapy. Although postimplantation stroke rates have been described in the context of bridge-to-transplant or mixed cohorts, stroke development is not well evaluated in patients who receive continuous-flow LVAD with a destination therapy indication. This report characterizes the stroke profile of a modern institutional cohort of patients undergoing destination therapy and evaluates their risk factors for stroke onset.

View Article and Find Full Text PDF